Jack Derwin
Markets and finance correspondent
Jack has worked as a business reporter for the better part of a decade, filing from Mexico, Spain, New Zealand and the Pacific. He has previously reported for The Asahi Shimbun, the second largest newspaper in the world, Business Insider and 7News amongst others.
Contact Jack via email or Signal.
The securities regulator was alerted to insider trading allegations involving ASX staff who sold shares before the company’s technology issues were made public.
A week dominated by activity on — and scandals surrounding — the ASX ended fittingly with results from the national stock exchange operator itself.
Fresh insider claims suggest the ASX's tech problems were widely known inside and outside of the company - long before they were acknowledged by it and regulators.
ASIC alleges Australia's primary exchange not only failed to keep the market informed but knowingly misled it. "The ASX is going to be an international laughing stock," said one former market official.
A 15 month ASIC investigation into a bungled technology project revealed “collective organisational failure” at the exchange operator.
The biotech company, one of the largest on the ASX, saw its share price drop despite strong profit growth. Here are three reasons why.
Experts say up to 10% of trades on the ASX could be 'tainted' by inside information. And insider traders are using more sophisticated techniques to get away with it.
ASIC says Australia’s public markets are among the cleanest in the developed world. But a number of recent questionable incidents including market-moving leaks call that into question.
The entrepreneur behind a failed bid for the troubled Sydney casino has broken his silence over the bizarre incident, revealing he has referred the matter to ASIC.
Investors hoping this week's market turmoil might increase the chances of a near-term rate cut were left sorely disappointed on Tuesday.
The ASX 200 lost 3.7%, Japanese stocks recorded their worst session since 1987 and cryptocurrencies plunged. One strategist described it as "the correction we had to have".
With one of Australia’s largest ‘licence for hire’ firms under a regulatory cloud, brokers are scrambling to attain their own AFSLs to protect their businesses.
The Kiwi investment bank has suffered a string of departures over the course of the year. And the latest wave following a raid by a rival may be the biggest yet.
The corporate regulator is growing increasingly concerned over the ‘de-equisitation’ of the ASX and it's considering cutting compliance in a bid to arrest the trend.
The Sydney-based debt fund aims to offer flexible options and compete with major players like Airtree and Blackbird.
The bruised market darling is setting a slow and steady path forward in the face of investor exuberance and media scrutiny over its bubbly market cap.
In Australia, ETFs are synonymous with passive investing. In the US, they’re anything but, as investors pump their portfolios with leverage and shorts.
A number of startups are emerging to cater to the longevity hype. Nick Bell might be Australia's number one advocate — and he admits it is a tough business.
Andrew Forrest's move away from green hydrogen, welcomed by investors, doesn't mean Fortescue has ended its goal of diversifying away from iron ore into more climate-friendly sectors.
While the defence tech company has a compelling story to tell, it clearly looked wildly overvalued. And a Capital Brief story on short sellers willing to bet on that was enough to send its share price plummeting.
The defence tech play, favoured by retail traders, has become 10-bagger in just 12 months and is more valuable on paper than some big ASX names. But sceptical short-sellers are circling.
On a quest to become Australia’s ‘alternative’ stock exchange, the NSX has stumbled before its turnaround campaign has even begun.
A new class of investment fund is emerging in Australia - looking for smaller targets than private equity firms, and holding them indefinitely.
Sydney healthcare startup Eucalyptus is the latest company to chase a piece of the growing longevity market with a $995-a-month program called Compound.
With its biggest revenue driver in weight loss drugs like Ozempic facing uncertainty, Eucalyptus is expanding into men's longevity. But its offering isn’t cheap.
The pharmacy software business boasts a star studded shareholder register and exposure to one of the hottest trends in the market - miracle weight loss drug Ozempic.
The Israel-headquartered investment broker, which has 1.5 million Australian users, expects further consolidation in the saturated industry.
The frosty sentiment towards the ASX among startups is thawing in the wake of the Guzman y Gomez IPO — just as the barriers to listing in the US get higher.
Having been burned by hype cycles before, Martin Currie Australia’s CIO sees a steep correction coming for both Australia’s biggest export and an overbought tech sector.
